ERBB2 and breast cancer: In this work, we hypothesised that further refinement of the clinically diagnosed HER2‐positive BC in an easily validated method which best reflects HER2 oncogenic activity and response to therapy utilising the existing knowledge of the biology and pathology of BC is needed.